ABC News
Turn on desktop notifications for breaking stories about interest?
OffOn
Phase 1 trials have begun in London for a new nasal vaccine.
• 8 min read
On Location: April 19, 2021
Catch up on the developing stories making headlines.J. Conrad Williams, Jr./Newsday via Getty Images, FILE
LONDON Trials have begun in London for the next generation of COVID-19 vaccines with the first dose for a new nasal vaccine being developed by the U.S. company Codagenix having been administered at a quarantine facility in London, it was announced Monday morning.
“This vaccine is one of the first of the next generation COVID-19 vaccines, it is a single dose, needle free, intranasal, live attenuated COVID-19 virus vaccine.” Cathal Friel, Executive Chairman, of Open Orphan, the company running the trials said in a statement.
Trials have begun in London for the next generation of COVID-19 vaccines with the first dose for a new nasal vaccine being developed by the U.S. company Codagenix.